Details of the Drug

General Information of Drug (ID: DMUPFLI)

• Drug Name: Deutetrabenazine
• Synonyms: Dutetrabenazine; Austedo; SD809; SD-809; SD 809; 1392826-25-3; Deutetrabenazine [USAN:INN]

Indication

Disease Entry	ICD 11	Status	REF
Huntington disease	8A01.10	Approved	[1]
Tardive dyskinesia	8A02.10	Approved	[2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 323.5
  Logarithm of the Partition Coefficient (xlogp); 2.9
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Clearance: The clearance of drug is 47 L/h []
  Elimination: In healthy subjects, about 75% to 86% of the deutetrabenazine dose was excreted in the urine, and fecal recovery accounted for 8% to 11% of the dose []
  Half-life: The concentration or amount of drug in body reduced by one-half in 9 - 10 hours []
  Metabolism: The drug is metabolized via the hepatic []
  Vd: The volume of distribution (Vd) of drug is 500 L []
• Chemical Identifiers:
  Formula: C19H27NO3
  IUPAC Name: (3R,11bR)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
  Canonical SMILES: [2H]C([2H])([2H])OC1=C(C=C2[C@H]3CC(=O)[C@@H](CN3CCC2=C1)CC(C)C)OC([2H])([2H])[2H]
  InChI: InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1/i3D3,4D3
  InChIKey: MKJIEFSOBYUXJB-VFJJUKLQSA-N
• Cross-matching ID:
  PubChem CID: 73437646
  CAS Number: 1392826-25-3
  DrugBank ID: DB12161
  TTD ID: D0E7ZU
  VARIDT ID: DR01127
  INTEDE ID: DR0445
  ACDINA ID: D00184
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Synaptic vesicle amine transporter (SLC18A2)	TTNZRI3	VMAT2_HUMAN	Modulator	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[4]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Huntington disease
• ICD Disease Classification: 8A01.10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Synaptic vesicle amine transporter (SLC18A2)	DTT	SLC18A2	2.69E-02	-0.04	-0.11
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.36E-01	1.62E-02	1.08E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Deutetrabenazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[6]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Deutetrabenazine and Oliceridine.	Acute pain [MG31]	[7]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Levalbuterol.	Asthma [CA23]	[8]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Deutetrabenazine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[9]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Deutetrabenazine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[10]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Selpercatinib.	Lung cancer [2C25]	[11]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Deutetrabenazine and Siponimod.	Multiple sclerosis [8A40]	[12]
Ozanimod	DMT6AM2	Major	Additive hypertensive effects by the combination of Deutetrabenazine and Ozanimod.	Multiple sclerosis [8A40]	[7]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Deutetrabenazine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Rucaparib.	Ovarian cancer [2C73]	[7]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Triclabendazole.	Parasitic worm infestation [1F90]	[7]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[13]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Deutetrabenazine and Lefamulin.	Pneumonia [CA40]	[14]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Deutetrabenazine 12 mg tablet	12 mg	Oral Tablet	Oral
Deutetrabenazine 6 mg tablet	6 mg	Oral Tablet	Oral
Deutetrabenazine 9 mg tablet	9 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
• [5] FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration.
• [6] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [7] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [8] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [9] Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
• [10] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [11] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [12] Cerner Multum, Inc. "Australian Product Information.".
• [13] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [14] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.